The role of the MAD2-TLR4-MyD88 axis in paclitaxel resistance in ovarian cancer

Despite the use of front-line anticancer drugs such as paclitaxel for ovarian cancer treatment, mortality rates have remained almost unchanged for the past three decades and the majority of patients will develop recurrent chemoresistant disease which remains largely untreatable. Overcoming chemoresi...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:PLoS One
Autori principali: Bates, Mark, Spillane, Cathy D., Gallagher, Michael F., McCann, Amanda, Martin, Cara, Blackshields, Gordon, Keegan, Helen, Gubbins, Luke, Brooks, Robert, Brooks, Doug, Selemidis, Stavros, O’Toole, Sharon, O’Leary, John J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Public Library of Science 2020
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7769460/
https://ncbi.nlm.nih.gov/pubmed/33370338
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0243715
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi